1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6155FD3B4A6E28E9485257C7600589921
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/155FD3B4A6E28E9485257C7600589921!OpenDocument
18
19OpenDocument
203.236.86.184
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Digital Technology » Social Media Excellence

Complimentary Excerpt: Pharma Social Media Listening: Adverse Event Reporting and Program Approval Process

DB Image

ID: MD-399


Features:

15 Info Graphics

8 Data Graphics

58 Metrics

15 Narratives


Pages/Slides: 4


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".

To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5291: "Pharma Social Media Listening: Adverse Event Reporting and Program Approval Process".

Industries Profiled:
Biotech; Professional Services; Pharmaceutical; Health Care; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
CSL Behring; Straumann; Pfizer; Boston Scientific; Astellas; Johnson & Johnson; Novartis; Shire; Amgen; Sanofi; EMD Serono; GlaxoSmithKline ; Abbvie

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.